Inflammation and Resolution Are Associated with Upregulation of Fatty Acid β-Oxidation in Zymosan-Induced Peritonitis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fujieda, Yusuke ^a,b   Manno, Atsushi ^b   Hayashi, Yasuhiro ^b   Rhodes, Nelson ^c   Guo, Lining ^c   Arita, Makoto ^d   Bamba, Takeshi ^a   Fukusaki, Eiichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c METABOLON INC   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; FATTY ACID; GAMMA INTERFERON; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CELL INFILTRATION; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENERGY METABOLISM; FATTY ACID OXIDATION; GLYCOLYSIS; INFLAMMATION; MALE; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERITONEAL CAVITY; PERITONEAL FLUID LEVEL; PERITONITIS; UPREGULATION;

ANIMALS; FATTY ACIDS; INFLAMMATION; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; PERITONITIS; ZYMOSAN;

ANIMALIA; MUS;

EID: 84878837533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066270     Document Type: Article

References (43)

1. Nathan C, Ding A, (2010) Nonresolving inflammation. Cell 140: 871-882.
2. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, et al. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325-332.
3. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N, (2011) Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 11: 629-647.
4. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, et al. (2012) Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 287: 10525-10534.
5. Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, et al. (2010) A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol 184: 1516-1525.
6. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, et al. (2011) Transcriptomic analyses of murine resolution-phase macrophages. Blood 118: e192-208.
7. Fujieda Y, Ueno S, Ogino R, Kuroda M, Jonsson TJ, et al. (2012) Metabolite profiles correlate closely with neurobehavioral function in experimental spinal cord injury in rats. PLoS One 7: e43152.
8. Lindon JC, Holmes E, Nicholson JK, (2007) Metabonomics in pharmaceutical R&D. FEBS J 274: 1140-1151.
9. Cash JL, White GE, Greaves DR, (2009) Chapter 17. Zymosan-induced peritonitis as a simple experimental system for the study of inflammation. Methods Enzymol 461: 379-396.
10. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E, (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81: 6656-6667.
11. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, et al. (2010) Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J 24: 2962-2975.
12. Tsugawa H, Bamba T, Shinohara M, Nishiumi S, Yoshida M, et al. (2011) Practical non-targeted gas chromatography/mass spectrometry-based metabolomics platform for metabolic phenotype analysis. J Biosci Bioeng 112: 292-298.
13. Tsugawa H, Tsujimoto Y, Arita M, Bamba T, Fukusaki E, (2011) GC/MS based metabolomics: development of a data mining system for metabolite identification by using soft independent modeling of class analogy (SIMCA). BMC Bioinformatics 12: 131.
14. Lommen A, (2009) MetAlign: interface-driven, versatile metabolomics tool for hyphenated full-scan mass spectrometry data preprocessing. Anal Chem 81: 3079-3086.
15. Yamada T, Tani Y, Nakanishi H, Taguchi R, Arita M, et al. (2011) Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J 25: 561-568.
16. Reid BN, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, et al. (2008) Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem 283: 13087-13099.
17. Wang W, Wang P, Chaudry IH, (1998) Pentoxifylline increases gut ketogenesis following trauma and hemorrhagic shock. Crit Care Med 26: 101-107.
18. Serhan CN, Chiang N, Van Dyke TE, (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
19. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, et al. (2009) Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206: 15-23.
20. Soehnlein O, Lindbom L, (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10: 427-439.
21. Hung ND, Kim MR, Sok DE, (2011) Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis. Br J Pharmacol 162: 1119-1135.
22. Schwab JM, Chiang N, Arita M, Serhan CN, (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
23. Gijon MA, Leslie CC, (1999) Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. J Leukoc Biol 65: 330-336.
24. Eltzschig HK, Sitkovsky MV, Robson SC, (2012) Purinergic signaling during inflammation. N Engl J Med 367: 2322-2333.
25. Csoka B, Nemeth ZH, Rosenberger P, Eltzschig HK, Spolarics Z, et al. (2010) A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 185: 542-550.
26. Hasko G, Pacher P, (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83: 447-455.
27. Shiomi Y, Nishiumi S, Ooi M, Hatano N, Shinohara M, et al. (2011) GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 17: 2261-2274.
28. Li PK, Lee JT, MacGillivray MH, Schaefer PA, Siegel JH, (1980) Direct, fixed-time kinetic assays for beta-hydroxybutyrate and acetoacetate with a centrifugal analyzer or a computer-backed spectrophotometer. Clin Chem 26: 1713-1717.
29. Liu TF, Vachharajani VT, Yoza BK, McCall CE, (2012) NAD+-dependent Sirtuin 1 and 6 Proteins Coordinate a Switch from Glucose to Fatty Acid Oxidation during the Acute Inflammatory Response. J Biol Chem 287: 25758-25769.
30. Bouter KP, Diepersloot RJ, van Romunde LK, Uitslager R, Masurel N, et al. (1991) Effect of epidemic influenza on ketoacidosis, pneumonia and death in diabetes mellitus: a hospital register survey of 1976-1979 in The Netherlands. Diabetes Res Clin Pract 12: 61-68.
31. Tan H, Wang C, Yu Y, (2012) H1N1 influenza: the trigger of diabetic ketoacidosis in a young woman with ketosis-prone diabetes. Am J Med Sci 343: 180-183.
32. Konig B, Koch A, Giggel K, Dordschbal B, Eder K, et al. (2008) Monocarboxylate transporter (MCT)-1 is up-regulated by PPARalpha. Biochim Biophys Acta 1780: 899-904.
33. Shriver LP, Manchester M, (2011) Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Sci Rep 1: 79.
34. Minnich A, Tian N, Byan L, Bilder G, (2001) A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280: E270-279.
35. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, et al. (2002) Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51: 901-909.
36. Pyper SR, Viswakarma N, Yu S, Reddy JK, (2010) PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8: e002.
37. Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, et al. (2010) PPARalpha contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10: 1261-1267.
38. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, et al. (2003) Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108: 2393-2399.
39. Ramanan S, Kooshki M, Zhao W, Hsu FC, Robbins ME, (2008) PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med 45: 1695-1704.
40. Guyton JR, (2007) Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18: 415-420.
41. Soudijn W, van Wijngaarden I, Ijzerman AP, (2007) Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27: 417-433.
42. Gambhir D, Ananth S, Veeranan-Karmegam R, Elangovan S, Hester S, et al. (2012) GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy. Invest Ophthalmol Vis Sci 53: 2208-2217.
43. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, et al. (2012) Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 32: 669-676.